Psychedelic From Ayahuasca May Fast-Track Depression Relief

After decades of relying on the same depression medications, researchers have found a naturally occurring compound that works faster and lasts longer than many existing treatments.

Scientists at Imperial College London tested DMT, a psychedelic ingredient found in the Amazonian brew ayahuasca, on 34 adults with clinical depression. The results surprised even the researchers: patients showed significant improvement after just one dose, with benefits lasting up to 12 weeks.

DMT earned the nickname "businessman's trip" because its effects last only 30 minutes when given intravenously, compared to two hours for psilocybin, the magic mushroom compound also being studied for depression. This shorter duration makes it easier for medical staff to monitor patients and manage the treatment in clinical settings.

The trial followed a careful two-stage approach. First, participants received either DMT or a placebo without knowing which. Two weeks later, everyone received DMT with full knowledge of what they were taking. Those who got the real drug in round one showed bigger drops in depression scores than the placebo group.

"When it comes to treating depression we're essentially still mainly using the same medications developed in the 1980s," said David Erritzoe, the study's lead researcher and clinical associate professor at Imperial College London. "But we know there are a large number of people for whom these treatments don't work."

Side effects like mild nausea and injection site discomfort were manageable and temporary. The study, published in Nature Medicine, represents a meaningful step forward, though larger trials are needed before DMT could become widely available as a treatment.

Why This Inspires

Depression affects hundreds of millions worldwide, and for many sufferers, existing medications either don't work or cause serious side effects like weight gain, sleep problems, and sexual dysfunction. The possibility of a fast-acting treatment that requires just one or two doses instead of daily pills for months represents a fundamental shift in how we might treat mental illness.

Scientists believe psychedelics like DMT promote "neuroplasticity," essentially rewiring neural connections in the brain that depression has disrupted. This biological mechanism differs completely from traditional antidepressants, offering hope for people who've tried everything else without success.

Liliana Galindo, a psychiatrist at the University of Cambridge, called the findings "a welcome glimmer of hope in the fight against depression." James Rucker from King's College London noted the growing evidence that psychedelic drugs may have "rapid and enduring antidepressant effects when given in a medically controlled, psychologically supportive setting."

The research continues a remarkable journey for substances once dismissed as merely recreational drugs, now emerging as potential breakthrough treatments for some of our most stubborn mental health challenges.